Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun BioPharma, Inc. Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun BioPharma Announces Pause in Enrollment of Clinical Trial of SBP-101 for Patients with Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Micro-cap Oncology Biotech Sun BioPharma Files for a $12 Million Nasdaq","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun BioPharma, Inc. Receives FDA Fast Track Designation for SBP-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Craig-Hallum Capital Group","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sun BioPharma, Inc. Closes $10.5 Million Public Offering of Common Stock and Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Sun BioPharma

    Menu

    Sun BioPharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sun BioPharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sun BioPharma, Inc. Closes $10.5 Million Public Offering of Common Stock and Warrants

              Details:

              Funding will support development of SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for the exocrine pancreas and pancreatic ductal adenocarcinoma.

              Lead Product(s): Diethyl dihydroxyhomospermine,Enzalutamide,Gemcitabine

              Therapeutic Area: Oncology Product Name: SBP-101

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Craig-Hallum Capital Group

              Deal Size: $10.5 million Upfront Cash: Undisclosed

              Deal Type: Public Offering September 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sun BioPharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Micro-cap Oncology Biotech Sun BioPharma Files for a $12 Million Nasdaq

              Details:

              The company's lead candidate, SBP-101, is a small molecule polyamine metabolic inhibitor delivered subcutaneously for the treatment of pancreatic cancer and solid tumors.

              Lead Product(s): Diethyl dihydroxyhomospermine,Enzalutamide,Gemcitabine

              Therapeutic Area: Oncology Product Name: SBP-101

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $12.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering July 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sun BioPharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sun BioPharma, Inc. Receives FDA Fast Track Designation for SBP-101

              Details:

              The company has received Fast Track Designation from the U.S. FDA for its lead product, SBP-101, being developed for firstline treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA) when administered in combination with gemcitabine and nab-paclitaxel.

              Lead Product(s): Diethyl dihydroxyhomospermine,Enzalutamide,Gemcitabine

              Therapeutic Area: Oncology Product Name: SBP-101

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sun BioPharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sun BioPharma Announces Pause in Enrollment of Clinical Trial of SBP-101 for Patients with Pancreatic Cancer

              Details:

              The COVID-19 pandemic has affected the conduct of clinical trials at US and Australian sites. Some cancer centers have redeployed resources to prioritize COVID-19 patient care activities.

              Lead Product(s): Diethyl dihydroxyhomospermine,Paclitaxel,Gemcitabine

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sun BioPharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sun BioPharma, Inc. Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium

              Details:

              SBP-101 was well tolerated in combination with gemcitabine and nab-paclitaxel.

              Lead Product(s): Diethyl dihydroxyhomospermine,Paclitaxel,Gemcitabine

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY